Publicacións en colaboración con investigadores/as de University of California, San Francisco (17)

2023

  1. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2022

  1. Semimechanistic models to relate noxious stimulation, movement, and pupillary dilation responses in the presence of opioids

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 11, Núm. 5, pp. 581-593

2020

  1. Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2’,2’-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer

    Clinical and Translational Science, Vol. 13, Núm. 3, pp. 608-617

2019

  1. Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies

    AAPS Journal, Vol. 21, Núm. 2

2018

  1. Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer

    European Journal of Pharmaceutical Sciences, Vol. 115, pp. 296-303

  2. Systematic modeling and design evaluation of unperturbed tumor dynamics in xenografts

    Journal of Pharmacology and Experimental Therapeutics, Vol. 366, Núm. 1, pp. 96-104

2016

  1. Modeling respiratory depression induced by remifentanil and propofol during sedation and analgesia using a continuous noninvasive measurement of pCO2

    Journal of Pharmacology and Experimental Therapeutics, Vol. 356, Núm. 3, pp. 563-573

2015

  1. Pharmacokinetic-pharmacodynamic modelling in anaesthesia

    British Journal of Clinical Pharmacology, Vol. 79, Núm. 1, pp. 72-84

  2. Relation between acute and long-term cognitive decline after surgery: Influence of metabolic syndrome

    Brain, Behavior, and Immunity, Vol. 50, pp. 203-208

  3. Sedation-analgesia with propofol and remifentanil: Concentrations required to avoid gag reflex in upper gastrointestinal endoscopy

    Anesthesia and Analgesia, Vol. 121, Núm. 1, pp. 90-96

2013

  1. Modeling the influence of the A118G polymorphism in the OPRM1 gene and of noxious stimulation on the synergistic relation between propofol and remifentanil: Sedation and analgesia in endoscopic procedures

    Anesthesiology, Vol. 118, Núm. 6, pp. 1395-1407

2000

  1. Modeling of the in vivo antinociceptive interaction between an opioid agonist, (+)-O-desmethyltramadol, and a monoamine reuptake inhibitor, (-)-O-desmethyltramadol, in rats

    Journal of Pharmacology and Experimental Therapeutics, Vol. 295, Núm. 1, pp. 352-359

  2. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O- desmethyltramadol, in rats

    Journal of Pharmacology and Experimental Therapeutics, Vol. 293, Núm. 2, pp. 646-653

1999

  1. Simple mixing device to reproducibly prepare cationic lipid-DNA complexes (lipoplexes)

    BioTechniques, Vol. 27, Núm. 2, pp. 286-290

1997

  1. A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex

    Clinical Pharmacology and Therapeutics, Vol. 61, Núm. 1, pp. 70-82

1994

  1. Semiparametric models for antagonistic drug interactions

    Journal of Applied Physiology, Vol. 76, Núm. 5, pp. 2224-2233

1993

  1. Tenoxicam: Acute dose‐dependent disposition studies in rats

    Journal of Pharmaceutical Sciences, Vol. 82, Núm. 8, pp. 851-853